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The Influence of
Antiretroviral Therapy on the
QTc Interval in an African
Cohort
To the Editor—Cardiovascular disease
in human immunodeficiency virus (HIV)
infection encompasses a wide range of
pathologic entities, including myocardial,
pericardial, and endocardial disease, ath-
erosclerosis, arrhythmias, and vasculitis.
The most common manifestations of
HIV-associated heart disease in sub-
Saharan Africa are pericarditis, cardiomy-
opathy, and pulmonary hypertension [1].
Coronary artery disease, lipodystrophy,
and metabolic syndrome, although com-
mon in developed countries, are tradi-
tionally thought to be less clinically
significant problems in the African sub-
continent [2]. It is well known that pro-
longation of the QTC interval can
predispose patients to potentially fatal
ventricular tachyarrhythmias, particularly
torsades de pointes, and thus is an in-
dependent predictor of cardiovascular
morbidity and mortality [3].
The aim of this study was to determine
whether there is an association between
antiretroviral (ARV) therapy and pro-
longed QT in HIV-positive ARV-treated
patients in Nairobi, Kenya. HIV-positive
adults from both inpatient and outpatient
departments at Aga Khan Teaching Hos-
pital, Nairobi, were enrolled with exclu-
sion criteria including any known cardiac
disease. Patients were enrolled into either
the ‘‘ARV-experienced’’ or ‘‘ARV-naive’’
arm of the study. The study was approved
by the local ethics committee, and writ-
ten informed consent obtained from all
patients.
A standard 12-lead electrocardiogram
was obtained in each patient, and a QTc
interval of .440 ms was considered pro-
longed. A total of 299 HIV-positive
patients were screened, 157 in the ARV-
experienced arm and 142 in the ARV-
naive control arm. A total of 27 patients in
the ARV-experienced arm and 12 in the
ARV-naive arm were excluded due to
protocol violations, leaving 130 patients in
each arm of the study (Table 1). QTC in-
terval prolongation was observed in 16.2%
of patients in the ARV-experienced group,
compared with 6.9% in the ARV-naive
control group (v2 5 5.43; P 5 .01); the
odds ratio was calculated as 2.5 with
a 95% confidence interval (1.01–6.67;
P 5 .02). The overall prevalence of QTc
prolongation across the whole subject co-
hort (ARV-experienced and ARV-
naive) was 11.5%. When patients were
divided by sex, prolongation was observed
in 11.3% of male and 11.8% of female
patients. The majority of patients with
QTc prolongation had QTc intervals of
440–469 ms, and none had QTc intervals
.500 ms (Table 2). There did not appear
to be any significant difference in preva-
lence of QTC prolongation between pa-
tients receiving a nonnucleoside analogue
reverse-transcriptase inhibitor–based regi-
men and those receiving a protease
inhibitor–based regimen (P 5 .78). In
addition, there was no significant differ-
ence in prevalence of QTc prolongation
between patients with World Health
Organization stage I/II HIV infection
and those with stage III/IV infection
(v2 5 0.52; P 5 .47), nor were
there correlations with CD4 cell count
(r 5 20.043), in contrast to findings of
other studies [4–6].
Literature on the association of QTc
prolongation and ARV therapy is surpris-
ingly sparse [7–10]. Our study shows that
ARV therapy does appear to confer
a significant increased risk of QTC
prolongation in HIV-positive patients,
compared with ARV-naive controls. The
increased risk has the potential to
predispose otherwise medically stable
patients to the development of potentially
fatal ventricular arrhythmias, although the
exact significance of an acquired asymp-
tomatic QTC prolongation in clinical
practice is yet to be established.
These results should remind physi-
cians of the importance of measuring
and monitoring the QTC interval for pa-
tients receiving ARV therapy and tailoring
management accordingly, to successfully
minimize cardiovascular morbidity and
mortality as ARV drugs become readily
available.
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Table 1. Baseline Characteristics of Study Patients
Patient characteristic ARV-experienced patients ARV-naive patients P
Age, mean 6 SD (range), y 42.0 6 8.15 (23–72) 42.5 6 8.17 (27–84) .60
Sex ratio, M-F 0.97:1 1:1.13 .62
Weight, mean 6 SD (range), kg 67.4 6 12.8 (42–123) 66.9 6 15.0 (40–112) .77
Hypertension, no. (%) 30 (23.1) 34 (26.2) .67
Diabetes mellitus, no. (%) 4 (3.1) 7 (5.4) .54
Excess alcohol intake, no. (%) 1 (0.8) 12 (9.2) .004
Current smoker, no. (%) 1 (0.8) 9 (6.9) .02
CD4 cell count, mean 6 SD, cells/mm3 344 6 269 (4–1308) 288 6 331 (3–2000) .14
Mean potassium level, mean 6 SD, mmol/l 3.9 6 0.47 4.0 6 0.46 .09
eGFR, mean 6 SD, mL/min 90.7 6 23.7 83.9 6 18.9 .03
Abbreviations: ARV, antiretroviral; eGFR, estimated glomerular filtration rate; SD, standard deviation.
CORRESPONDENCE d CID 2012:54 (1 February) d 449
Downloaded from https://academic.oup.com/cid/article-abstract/54/3/448/301645/The-Influence-of-Antiretroviral-Therapy-on-the-QTc
by Aga Khan University user
on 06 September 2017
